Federal law narrowed to clear path for abortion medication by mail

What it does

This bill narrows the scope of the Comstock Act—a 19th-century federal law that bans mailing obscene materials—by removing language that has been interpreted to restrict abortion-related materials and services. It strikes references to 'indecent' content, 'articles of immoral use or tendency,' and explicit language linking the law to abortion, replacing broad language with a narrower focus on 'obscene materials' only. The effect is to reduce legal uncertainty around mailing abortion-related information, medications, and services.

Why we flagged it

The bill's operative mechanism is to narrow the Comstock Act by removing language that has been read to restrict abortion-related materials and commerce. It does not legalize abortion itself but removes a federal criminal barrier to mailing abortion information and medications.

What the text implies

• Removes 'indecent' standard from Comstock Act, potentially narrowing federal obscenity law's reach beyond abortion context—unclear whether other 'indecent' materials (e.g., sexually explicit but non-obscene content) remain restricted under other provisions.
• Strikes cross-reference to postal statute (39 U.S.C. § 3001(e)) without restating its content; effect on postal service's independent authority to restrict materials is unclear from this text alone.
• Tariff Act amendment removes 'immoral' standard from customs inspection authority; scope of remaining restrictions on imported materials is not fully apparent from the bill's language.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill removes criminal restrictions on mailing abortion-related materials and information, reducing legal barriers to access and speech. Citizens seeking abortion information or medication, and providers offering them, face lower legal risk and greater clarity about what is permitted.

Who stands to gain

• pharmaceutical companies (abortion medication manufacturers and distributors)
• telehealth and mail-order pharmacy providers
• abortion service providers and clinics

Named in the bill

18 U.S.C. § 552, 18 U.S.C. § 1461, 18 U.S.C. § 1462, 19 U.S.C. § 305 (Tariff Act of 1930), 39 U.S.C. § 3001(e), Comstock Act, U.S. Postal Service, U.S. Customs and Border Protection

Where it stands

28 cosponsors: 27 Democrats, 1 Independents.

• Mar 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 11, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $90,000 in lobbying spend. A filing names 96 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Tina Smith, the sponsor, reported $-40,500 in PAC receipts in the 2026 cycle.

• Center for Reproductive Rights — $70,000 on 1 filing
• National Council of Jewish Women — $20,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.